Comprehensive Molecular Characterization Reveals Genomic and Transcriptomic Subtypes of Metastatic Urothelial Carcinoma.
J Alberto Nakauma-González, Maud Rijnders, Job van Riet...
https://pubmed.ncbi.nlm.nih.gov/35086719/Actively Recruiting
Led by The Netherlands Cancer Institute · Updated on 2024-01-24
1550
Participants Needed
36
Research Sites
13 weeks
Total Duration
Researchers are studying the use of targeted anticancer drugs in patients with advanced cancer who have specific molecular changes in their tumors. This study aims to describe how well these targeted drugs work and their side effects when prescribed based on a tumors genetic or protein profile. It focuses on patients with advanced solid tumors, multiple myeloma, or B cell non-Hodgkin lymphoma who have no standard treatment options left and have acceptable health status and organ function. Participants receive targeted cancer drugs selected from a list of approved therapies matched to their tumors molecular profile. A molecular tumor board and study coordinators help determine the best drug choice. Before treatment, patients provide a fresh tumor biopsy for genetic analysis. The study includes many drugs, including Panitumumab, Olaparib, Dabrafenib, and several others, some given alone or in combination, according to the tumor profile. Treatment eligibility and drug-specific criteria are confirmed before starting therapy. Throughout the study, participants are monitored for tumor response, disease stability, survival, and treatment side effects. Researchers collect data on tumor changes, progression-free survival, overall survival, and how long patients remain on treatment. Next generation sequencing on tumor samples provides additional biomarker information. The study continues to follow patients for up to one year after treatment to assess outcomes and safety.
CONDITIONS
The Drug Rediscovery Protocol (DRUP Trial)
E
E.E. Voest, prof.
K
K. Verkerk, MD
Explore thousands of other clinical trials that might be a better match.
Sign up to get personalized trial recommendations delivered to your inbox.
Already have an account? Log in here
The Netherlands Cancer Institute
Lead Sponsor
Amgen
Collaborating Sponsor
You may qualify if you...
You will not qualify if you...
Duration - 2 to 4 weeks
Participants are screened for eligibility to participate in the trial.
1 visit (in-person)
Duration - Approximately 6 months after treatment initiation (estimated average)
Participants receive targeted anticancer drugs matched to their tumor's molecular profile. Treatment continues until disease progression or discontinuation.
Regular visits during treatment as per protocol
Duration - Up to 1 year after study completion
Participants are monitored for progression-free survival and overall survival outcomes after completing treatment.
Periodic follow-up visits for up to 1 year
Study Type
INTERVENTIONAL
Masking
NONE
Allocation
NON_RANDOMIZED
Model
PARALLEL
Primary Purpose
TREATMENT
Number of Arms
37
Have more questions? Get in touch with our team for quick support
J Alberto Nakauma-González, Maud Rijnders, Job van Riet...
https://pubmed.ncbi.nlm.nih.gov/35086719/K Verkerk, A C Spiekman, S F Haj Mohammad...
https://pubmed.ncbi.nlm.nih.gov/41986720/Birgit S Geurts, Laurien J Zeverijn, Lindsay V M Leek...
https://pubmed.ncbi.nlm.nih.gov/38630551/Birgit S Geurts, Thomas W Battaglia, J Maxime van Berge Henegouwen...
https://pubmed.ncbi.nlm.nih.gov/36870947/Laurien J Zeverijn, Eleonora J Looze, Subotheni Thavaneswaran...
https://pubmed.ncbi.nlm.nih.gov/37424386/J M van Berge Henegouwen, H van der Wijngaart, L J Zeverijn...
https://pubmed.ncbi.nlm.nih.gov/35598186/The Netherlands Cancer Institute
Lead Sponsor
Amgen
Collaborating Sponsor